更新于：2024-06-20
Ciclopirox olamine
环吡酮胺
更新于：2024-06-20
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 加拿大 (1985-01-01) |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C14H24N2O3 |
InChIKeyMBRHNTMUYWQHMR-UHFFFAOYSA-N |
CAS号41621-49-2 |
关联
12
项与 环吡酮胺 相关的临床试验A Phase I, Double-blind, Randomized, Placebo-controlled Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers
Evaluation of Skin Safety of a test product Ciclopirox Olamine Cream USP 1percent w/w for Primary Skin Irritation Using Skin lrritation Test (Patch Test in Humans) IS 4011 2018 Guidelines
Double-blind, randomised clinical study comparing efficacy and safety of Ciclopirox Olamine Cream 10 mg/g (Test) vs. Batrafen® Cream (Reference) vs. Vehicle in patients with skin mycoses
100 项与 环吡酮胺 相关的临床结果
登录后查看更多信息
100 项与 环吡酮胺 相关的转化医学
登录后查看更多信息
100 项与 环吡酮胺 相关的专利（医药）
登录后查看更多信息
235
项与 环吡酮胺 相关的文献（医药）2023-12-26Blood advances
Ciclopirox ethanolamine preserves the immature state of human HSCs by mediating intracellular iron content
Article
作者: Larsson, Jonas ; Will, Britta ; Baudet, Aurélie ; Karlsson, Christine ; Miharada, Natsumi ; Rak, Justyna ; Talkhoncheh, Mehrnaz Safaee ; Zemaitis, Kristijonas ; Ek, Fredrik ; Oburoglu, Leal ; Kao, Yun-Ruei ; Subramaniam, Agatheeswaran ; Pietras, Kristian ; Alattar, Abdul Ghani ; Olsson, Roger ; Rydström, Anna
Abstract:
Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clinical benefit are highly sought after. To elucidate regulatory mechanisms governing the maintenance and propagation of human HSCs ex vivo, we screened libraries of annotated small molecules in human cord blood cells using an optimized assay for detection of functional HSCs during culture. We found that the antifungal agent ciclopirox ethanolamine (CPX) selectively supported immature CD34+CD90+ cells during culture and enhanced their long-term in vivo repopulation capacity. Purified HSCs treated with CPX showed a reduced cell division rate and an enrichment of HSC-specific gene expression patterns. Mechanistically, we found that the HSC stimulating effect of CPX was directly mediated by chelation of the intracellular iron pool, which in turn affected iron-dependent proteins and enzymes mediating cellular metabolism and respiration. Our findings unveil a significant impact of iron homeostasis in regulation of human HSCs, with important implications for both basic HSC biology and clinical hematology.
2023-10-22Life (Basel, Switzerland)
Pityriasis Versicolor-A Narrative Review on the Diagnosis and Management.
Review
作者: Pogorzelska-Antkowiak, Anna ; Kubisiak-Rzepczyk, Honorata ; Łabędź, Nina ; Navarrete-Dechent, Cristian ; Bowszyc-Dmochowska, Monika ; Pietkiewicz, Paweł
This narrative review presents a comprehensive overview of the diagnosis and management of pityriasis versicolor (PV), a common superficial fungal infection caused by the yeast Malassezia. PV is characterised by scaly hypopigmented or hyperpigmented patches, primarily affecting the upper trunk, neck, and upper arms. Regarding commensal interactions, Malassezia utilises nutrient sources without affecting the human host. In cases of pathogenicity, Malassezia can directly harm the host via virulence factors or toxins, or indirectly by triggering damaging host responses. The diagnosis typically relies on recognising characteristic clinical features. Due to the wide variability in its clinical presentation, recognising the differential diagnosis is critical. In this paper, we discuss the clinical differentials, with their dermatoscopic presentation, but also describe a range of helpful diagnostic techniques (microscopy, conventional and ultraviolet-induced fluorescence dermatoscopy, and confocal microscopy). Topical therapies are the primary treatment for PV, encompassing non-specific antifungal agents like sulphur with salicylic acid, selenium sulphide 2.5%, and zinc pyrithione. Additionally, specific topical antifungal medications with either fungicidal or fungistatic properties may also be incorporated into the topical treatment regimen, such as imidazoles, allylamines, and ciclopirox olamine. Systemic therapies might occasionally be used. Patient education and the promotion of good personal hygiene are pivotal to reduce the risk of recurrence. In recurrent cases, particularly during warmer and more humid periods, prolonged prophylaxis with topical agents should be considered.
2023-09-03Cancers
High-Throughput Drug Screening Revealed That Ciclopirox Olamine Can Engender Gastric Cancer Stem-like Cells.
Article
作者: Mesquita, Patrícia ; Figueira, Paula ; Maia, André Filipe ; Lima, Raquel T ; Almeida, Raquel ; Pereira, Carlos Filipe ; Pádua, Diana ; Pombinho, António ; Peixoto, Joana ; Pinto, Mariana
Cancer stem cells (CSCs) are relevant therapeutic targets for cancer treatment. Still, the molecular circuits behind CSC characteristics are not fully understood. The low number of CSCs can sometimes be an obstacle to carrying out assays that explore their properties. Thus, increasing CSC numbers via small molecule-mediated cellular reprogramming appears to be a valid alternative tool. Using the SORE6-GFP reporter system embedded in gastric non-CSCs (SORE6-), we performed a high-throughput image-based drug screen with 1200 small molecules to identify compounds capable of converting SORE6- to SORE6+ (CSCs). Here, we report that the antifungal agent ciclopirox olamine (CPX), a potential candidate for drug repurposing in cancer treatment, is able to reprogram gastric non-CSCs into cancer stem-like cells via activation of SOX2 expression and increased expression of C-MYC, HIF-1α, KLF4, and HMGA1. This reprogramming depends on the CPX concentration and treatment duration. CPX can also induce cellular senescence and the metabolic shift from oxidative phosphorylation (OXPHOS) to glycolysis. We also disclose that the mechanism underlying the cellular reprogramming is similar to that of cobalt chloride (CoCl2), a hypoxia-mimetic agent.
1
项与 环吡酮胺 相关的新闻（医药）100 项与 环吡酮胺 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 外阴阴道念珠菌病 | 中国 | 1989-01-01 | |
| 脂溢性皮炎 | 中国 | 1989-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 足癣 | 临床3期 | - | 2003-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 顧構鏇繭醖觸蓋壓製衊(鏇願蓋衊簾糧鑰膚築鹽) = 獵構網憲繭鬱積鑰積顧 獵願築壓鑰夢積淵願鏇 (糧齋衊襯窪繭夢膚觸積 ) 更多 | 积极 | 2019-11-05 | |||
N/A | 553 | (Test Product) | 願網獵廠醖夢醖鑰範糧(餘獵構艱憲壓鑰襯憲廠) = 網顧鏇積窪糧鹹齋蓋壓 膚襯膚鏇淵繭範醖築餘 (鏇願構糧積繭觸夢鹽範, 簾鏇顧蓋膚齋鏇壓積構 ~ 襯鬱膚選鏇齋襯觸壓廠) 更多 | - | 2012-12-17 | ||
(Reference Product) | 願網獵廠醖夢醖鑰範糧(餘獵構艱憲壓鑰襯憲廠) = 繭膚廠築鹽夢鹽鏇淵網 膚襯膚鏇淵繭範醖築餘 (鏇願構糧積繭觸夢鹽範, 願鹽網鑰鏇餘鏇壓窪鬱 ~ 鹽餘範夢衊選鬱廠膚窪) 更多 | ||||||
临床3期 | 561 | (Test Product) | 鹹觸夢繭鹹艱積構鬱繭(衊範膚壓鹹製築鏇鏇蓋) = 簾網繭範構糧襯夢獵網 餘鑰遞願鹹糧鏇蓋範艱 (構鹽顧鬱艱遞廠衊鏇構, 夢醖壓鏇鑰鹽製觸繭衊 ~ 製鏇繭淵膚遞鬱蓋鹹襯) 更多 | - | 2012-06-19 | ||
(Reference Product) | 鹹觸夢繭鹹艱積構鬱繭(衊範膚壓鹹製築鏇鏇蓋) = 壓顧憲憲構遞築艱膚齋 餘鑰遞願鹹糧鏇蓋範艱 (構鹽顧鬱艱遞廠衊鏇構, 鹹願憲選簾鹹積蓋鹽膚 ~ 艱積選獵遞鹽窪糧蓋艱) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用